Literature DB >> 9410469

Effect of recombinant interleukin-6 and thrombopoietin on isolated guinea pig bone marrow megakaryocyte protein phosphorylation and proplatelet formation.

R M Leven1, B Clark, F Tablin.   

Abstract

Guinea pig bone marrow megakaryocytes were isolated and cultured on collagen gels to promote proplatelet formation. In control cultures 15.6% of the cells formed proplatelets. Both IL6 and TPO stimulated dose dependent increases in the percent of proplatelet forming cells up to 26.7% at 100ng/mal IL6 and 26.8% at 100 ng/ml TPO. IL1 and IL3 had no effect on proplatelet formation. IL3 in combination with IL6 and TPO blocked the increase in proplatelet formation observed with IL6 or TPO alone. IL3 was also found to stimulate thymidine incorporation in megakaryocytes. The role of phosphorylation in proplatelet formation was studied using certain inhibitors. The tyrosine kinase inhibitor genestien had no effect on proplatelet formation at concentrations up to 100 microg/ml. The phosphatase inhibitors calyculin A and okadaic acid both inhibited proplatelet formation. Studies on protein phosphorylation revealed that IL6, but not TPO, stimulated phosphorylation of JAK1, JAK2 and MAP kinase. TPO did stimulate tyrosine phosphorylation of Tyk-2. Although IBMX stimulated proplatelet formation, it inhibited phosphorylation of JAK1 and MAP kinase. Adhesion of megakaryocytes to collagen gel also inhibited phosphorylation of JAK1 and JAK2, while MAP kinase phosphorylation was unaffected. These data show that IL6 and TPO stimulate megakaryocyte proplatelet formation. In addition, although these cytokines increase phosphorylation of signal transduction proteins in the JAK/STAT pathway, it appears that a different signal transduction pathway regulated by a combination of phosphatase activity and cAMP levels, leads to proplatelet formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9410469     DOI: 10.1006/bcmd.1997.0142

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer.

Authors:  Kyung Hee Kim; Tae Yun Park; Ji Yeun Lee; Sang-Min Lee; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Seok-Chul Yang
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

2.  Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.

Authors:  Sonja Badovinac; Marta Korsic; Davorka Mursic; Miroslav Samarzija; Branka Cucevic; Mihovil Roglic; Marko Jakopovic
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Craig D Hyland; Emma C Josefsson; Marion Lebois; Jian-Guo Zhang; Tracey M Baldwin; Ladina Di Rago; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

4.  A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer.

Authors:  Qiuyao Zeng; Ning Xue; Danian Dai; Shan Xing; Xia He; Shibing Li; Yi Du; Chumei Huang; Linfang Li; Wanli Liu
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

5.  Calorie restriction with regular chow, but not a high-fat diet, delays onset of spontaneous osteoarthritis in the Hartley guinea pig model.

Authors:  Lauren B Radakovich; Angela J Marolf; Lauren A Culver; Kelly S Santangelo
Journal:  Arthritis Res Ther       Date:  2019-06-13       Impact factor: 5.156

Review 6.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.